The digital health sector is entering a phase of consolidation and clinical validation, moving beyond the pandemic-era boom of point solutions toward integrated care models. Recent quarterly earnings, regulatory approvals, and venture funding data indicate a recalibrated market where reimbursement clarity and evidence generation—rather than user acquisition—dictate survival. This report examines the key developments across virtual care, remote patient monitoring (RPM), and AI-assisted diagnostics over the past six months.

Virtual Care Shifts from Volume to Value-Based Contracting

The most significant structural change is the migration of telehealth from episodic visits to chronic care management under value-based arrangements. Teladoc Health and Amwell, the two largest pure-play telehealth firms, have both reported that over 40% of their commercial contracts now include risk-sharing components tied to clinical outcomes or total cost of care reduction. This is a marked departure from the fee-for-service model that dominated 2020-2022.

“We are seeing payers refuse to reimburse standalone virtual visits without a documented link to reduced hospital admissions,” said Dr. Elena Vasquez, a health policy researcher at the Brookings Institution. “The winners are platforms that embed RPM data, social determinants screening, and pharmacy adherence into a single workflow.” In response, Amwell announced its Converge platform upgrade in May, which integrates continuous glucose monitors and blood pressure cuffs directly into the telemedicine encounter, allowing physicians to adjust treatment plans in real time rather than relying on patient self-reports.

FDA’s Predetermined Change Control Plan Opens Door for Adaptive AI

Regulatory clarity is accelerating AI adoption. In April, the U.S. Food and Drug Administration (FDA) issued its final guidance on Predetermined Change Control Plans (PCCPs) for machine learning-enabled medical devices. This framework allows manufacturers to update algorithms without requiring new premarket submissions, provided they specify the intended modifications and validation protocols in advance.

The first major beneficiary is cardiology. HeartFlow’s non-invasive FFR-CT analysis received PCCP clearance for its plaque quantification module, enabling the software to incorporate new imaging data from low-dose CT scanners without a separate 510(k) filing. Similarly, Eko Health’s AI stethoscope algorithm for detecting low ejection fraction gained PCCP status, allowing the company to refine its neural network as it processes more diverse patient populations.

“The PCCP is the single most important regulatory innovation since the 21st Century Cures Act,” argued Marcus Chen, a partner at the digital health law firm Foley & Lardner. “But it imposes a heavy post-market surveillance burden. Companies must now track real-world performance metrics—false positive rates, demographic performance gaps—and report them quarterly. This is shifting engineering resources from feature development to monitoring infrastructure.”

Remote Patient Monitoring Faces Reimbursement Cliff in Medicare

While AI diagnostics advance, RPM programs are confronting a reimbursement recalibration. In March, the Centers for Medicare & Medicaid Services (CMS) released its 2026 Physician Fee Schedule proposed rule, which suggests a 15% reduction in reimbursement for CPT code 99453 (RPM device setup) and a 10% cut for CPT 99454 (device supply with daily monitoring). CMS argues that device costs have fallen sharply and that initial setup is increasingly automated through Bluetooth pairing.

Industry response has been swift. The American Telemedicine Association (ATA) submitted formal comments in June, citing data from 14 health systems showing that RPM-driven blood pressure control reduced stroke-related hospitalizations by 22% over 12 months. “Cutting the supply code without adjusting the monitoring code creates a perverse incentive for vendors to bill more days than clinically necessary,” said ATA’s policy director, Sarah Kim. “We need a bundled payment for 30-day post-discharge monitoring, not piecemeal cuts.”

Notably, private payers are diverging from CMS. UnitedHealth’s Optum and Elevance Health both announced expanded RPM coverage for postpartum hypertension and pediatric asthma in Q2, with higher per-member-per-month rates than Medicare’s proposed levels. This divergence suggests a two-tier market: Medicare leading on cost containment, commercial plans competing on member experience.

Generative AI in Clinical Documentation Reaches Tipping Point

Ambient AI scribes have moved from novelty to standard practice. Ambient Clinical Analytics, Nuance’s DAX Copilot, and Abridge all report doubling their enterprise deployments in the first half of 2025. The key driver is not physician satisfaction but burnout reduction metrics. A multi-site study published inJAMA Internal Medicinein May found that ambient AI documentation reduced after-hours charting time from 1.8 hours to 0.4 hours per day, with a 31% decrease in documentation-related burnout scores.

However, a new concern is emerging: “hallucinated” clinical data. A retrospective audit by the Mayo Clinic of 10,000 AI-generated notes found that 4.2% contained fabricated vitals or medication dosages, often carried over from previous notes. In response, Epic and Oracle Health have added mandatory “AI provenance” flags that require clinicians to verify any numeric value not directly imported from a connected device. “The scribe is a listener, not a recorder,” warned Dr. James O’Connor, chief medical information officer at a large Midwest health system. “We now require a manual confirmation step for all medication changes. It slows the workflow slightly but eliminates the liability.”

Funding Environment: Quality Over Quantity, with a Focus on Behavioral Health

Venture funding in digital health reached $9.2 billion in H1 2025, down 28% year-over-year, according to Rock Health. Yet the median round size increased to $18 million, indicating that investors are concentrating capital into fewer, later-stage companies. The most active segment is AI-enabled behavioral health, where Woebot Health secured $90 million in Series C for its chatbot-based CBT platform, and Spring Health raised $120 million to expand its AI-driven therapist matching across employer clients.

“Investors are no longer chasing ‘AI for AI’s sake,’” said Rachel Lee, a general partner at Flare Capital Partners. “They want evidence of engagement persistence—patients staying in care beyond four weeks—and integration with existing EHR workflows. Standalone consumer apps with high churn are struggling to raise bridge rounds.”

International Perspective: Europe’s Health Data Space and China’s Telemedicine Crackdown

Globally, the European Health Data Space (EHDS) entered its implementation phase in June, mandating that all member states make electronic health records interoperable by 2027. This has created a compliance rush among U.S. digital health vendors operating in Europe, as they must now support HL7 FHIR R5 and the new EU Patient Summary format. Meanwhile, China’s National Health Commission issued stricter guidelines in April requiring all telemedicine prescriptions to include a real-time video consultation, effectively banning text-only prescription services. This has slowed the growth of platforms like JD Health and Ping An Good Doctor but has not reversed their profitability.

Outlook: The Next 12 Months

The consensus among analysts is that 2026 will be the year of “digital health as infrastructure.” Key trends to watch include: (1) the expansion of CMS’s new Transitional Care Management codes for AI-powered post-discharge follow-up; (2) the first FDA approvals for autonomous AI diagnostic systems that do not require clinician over-read in low-risk settings (e.g., diabetic retinopathy screening in retail clinics); and (3) the emergence of employer-sponsored digital health formularies, where companies like Accolade and Included Health negotiate bundled rates for mental health, MSK, and fertility benefits from a single vendor.

As Dr. Vasquez concluded, “The era of pilot projects is over. Health systems are now terminating underperforming digital health contracts at renewal. The vendors that survive will be those that can demonstrate, with auditable data, that they reduce the total cost of care for a defined population. That is a higher bar, but it is also a more durable business model.” For now, the sector’s trajectory is defined not by breakthrough gadgets but by the unglamorous work of protocol integration, reimbursement negotiation, and clinical validation.